Phase 1b schema and treatment duration. The phase 1b treatment schema is presented in panel A. Data on treatment duration are presented in panel B for patients in the all-treated population, with each bar representing an individual patient. Patients are ordered by the study initial dose date and color-coded by DLBCL subtype. The indicated lenalidomide dose was given in combination with 560 mg/day ibrutinib and 375 mg/m² IV rituximab. PO, per os.